

THURSDAY, October 8th, 2015

Individual arrival

19.00 Welcome Dinner

FRIDAY, October 9th, 2015


Introduction	Topic	Speaker
07:30 - 08:00	Registration/Light breakfast	
08:00 - 08:05	Welcome to the IBCN Meeting/Introduction of Members/Attendees	Peter Goebell/Ashish Kamat
08:05 - 08:15	Welcome to Athens/housekeeping rules	Antonia Vlahou

Keynote	Immuno-Oncology for Urothelial Carcinoma	Chair: Ashish Kamat
08:15 - 09:15	The landscape of Immuno-Oncology in bladder cancer - trials and results	Thomas Powles

Research in progress	Immuno-oncologic approaches	
09:15 - 09:45	Intravesical gene therapy: Update Results	Colin Dinney
09:15 - 09:45	Immune response to BCG in preclinical models of bladder cancer - the role of myeloid cells	Molly Ingersoll
09:45 - 10:00	A novel virotherapy in Bladder Cancer	Per Sonne Holm
10:00 - 10:15	Markers of response to neoadjuvant CTX in the context of PD-L1 Status and Related Immunological Factors	Trinity Bivalacqua
10:15 - 10:30	Evolving strategies in immunotherapy for urothelial cancer	Piyush K. Agarwal

Research in progress	Opportunities and advances	
10:30 - 10:45	Recent advances in immunohistochemistry of urothelial carcinoma and its variants	Charles Guo
10:45 - 11:00	BCMolMED and TransBioBC Initiatives: Implementation of proteomic bio-markers as diagnostic tools	Maria Frantzi
11:00 - 11:15	Mycobacterial Cell Wall Complex: Updated Results of Phase 2 trial	Michael Berendt

Coffee break 11:15 - 11:30



FRIDAY, October 9th, 2015

Project/trial updates	Topic	Chair: Colin Dinney
11:30 - 11:50	Challenges for bladder cancer epidemiologists	Núria Malats
11:50 - 12:05	Why I got bladder cancer...	Bart Kiemeneij
12:05 - 12:20	New promising trials in NMIBC	Toine van der Heijden


	Network and Industry: Immuno-Oncology Pipeline Talks and Discussion	Chair: Peter J. Goebell
12:20 - 12:50	Heat Biologics – NMIBC development program	Melissa Price
12:50 - 13:20	Check point inhibitors in NMIBC	Steve Kauf

Lunch break 13:20 - 14:00

Research in progress	Advanced Bladder Cancer	Chair: Bart Grossman
14:00 - 14:15	Pathways of clinical research and collaborative neoadjuvant trials	Andrea Necchi
14:15 - 14:30	Current Status, Paradigms, and Advances in Trimodality Therapy	Jason A. Efstathiou
14:30 - 14:45	Targeting lactate transport in MiBC	Tilman Todenhoefer
14:45 - 15:00	Immunoresponses, tumordraining nodes and immuno-oncology in bladder	Amir Sherif
15:00 - 15:15	Adoptive immunotherapy with sentinel node derived T cells in MiBC	Ola Wilquist
15:15 - 15:30	HDAC inhibition for radio sensitisation of MiBC	Anne Kiltie
15:30 - 15:45	Molecular profiling of preclinical models - insight for clinical trial design	Petros Grivas

Coffee break 15:45 - 16:00

Project/trial updates	Topic	Chair: Colin Dinney
16:00 - 16:15	E2F3 transcription factor modulates the immune microenvironment	Kamal Pohar
16:15 - 16:30	Predicting therapy response strategies	Marta Sanchez-Carbayo
16:30 - 16:45	Emmprin as predictor of cisplatin-response in advanced bladder cancer	Tammer Hemdan
16:45 - 17:00	Next Generation Sequencing of Upper Tract Urothelial Carcinoma	John P. Sfakianos



FRIDAY, October 9th, 2015

Guided visit to the Acropolis 17:15 – 20:00



Reconvene for Dinner 20:15

SATURDAY, October 10th, 2015

General assembly – members only 08:00 – 08:45

08:00 – 08:45	Agenda will be provided to members
----------------------	------------------------------------


	Network and Industry: Markers <i>Pipeline Talks and Discussion</i>	Chair: Ashish Kamat
08:45 – 09:15	Genentech	t.b.c.
09:15 – 09:45	Janssen-Cilag	t.b.c.

Research in progress	Markers in Bladder Cancer	Chair: Peter J. Goebell
09:45 – 10:00	Role of bladder cancer derived exosomes in	Kerstin Junker
10:00 – 10:15	Is the PI3K Signaling pathway targetable in Bladder Cancer?	Roman Nawroth
10:15 – 10:30	COST application – and beyond...	Sita Vermeulen
10:30 – 10:45	Opportunity for IBCN/Tissue Collection in Multicenter Trial of Blue Light Cystoscopy	Ashish Kamat

Coffee break 10:45 – 11:00

	Plenary discussion on prepared topics / Working group report	Chair: Bernd J. Schmitz-Dräger
11:00 – 11:30	Group 1: Molecular Markers	Bernd J. Schmitz-Dräger
11:30 – 12:00	Group 2: Advanced Disease	Roman Nawroth
12:00 – 12:30	Group 3: Industry, knowledge & trials	Peter J. Goebell/Ashish Kamat

Lunch break 12:30 – 13:15



SATURDAY, October 10th, 2015

Research in progress	Markers in Bladder Cancer	Chair: Antonia Vlahou
13:15 - 13:30	Serum tumor markers in bladder cancer- is there a role?	Sia Daneshmand
13:30 - 13:45	Exome and targeted sequencing of NMIBC	Margaret Knowles
13:45 - 14:00	Intratumor Heterogeneity of FGFR3 Mutations in MIBC: Implications for Peri-	Bas van Rhijn
14:00 - 14:15	Ureteroscopy prior to nephroureterectomy - a risk factor for bladder recurrence?	Alex Sankin
14:15 - 14:30	Development and Validation of a molecular urine test for Bladder Cancer detection	Lourdes Mengual
14:30 - 14:45	Targeting Chondroitin Sulfate glycosaminoglycans in bladder cancer	Mads Daugaard
14:45 - 15:00	Targeting glycans in cisplatin-resistant bladder cancer with a naturally occurring parasite-host anchor protein	Roland Seiler
15:00 - 15:15	Circulating tumor cells for clinical decision making in MiBC	Joost Boormans

Wrap-up & closing remarks		
15:15 - 15:30	IBC Board – Kiemeney, Schmitz-Dräger, Nawroth, Goebell, Kamat	